Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Anti-Annexin V Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, HRP-labelled antibody
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

RAF002R 96 wells (1 kit)
PubMed Product Details
Technical Data


Sandwich ELISA, HRP-labelled antibody


Serum, Cell culture supernatant

Sample Requirements

50 µl/well


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

6.25–400 ng/ml

Limit of Detection

1.18 ng/ml

Intra-assay (Within-Run)

CV = 2.0%

Inter-assay (Run-to-Run)

CV = 3.8%

Spiking Recovery


Dilutation Linearity



Research topic



Annexins are a family of calcium-dependent phospholipid-binding proteins. They are abundant in the eukaryotic kingdom.Though structurally well investigated the in vivo function of the annexins is still unclear.. They definitively belong to a family of ubiquitous cytoplasmic proteins involved in signal transduction. All annexins have been shown to have putative binding site for protein kinases C but only annexin V would possess a potential pseudo-substrate site. Thus annexin V seems to modulate the activity of some PKCs on thein substrates. Annexin V was found to play a major role in matrix vesicle-initiated cartilage calcification as a collage-regulated calcium channel. Annexin V’s preferential binding partner is phosphatidylserine (PS). PS is predominantly located in membrane leaflets, which face the cytosol. However, recent findings show that each cell type has the molecular machinery to expose PS at its cell surface. This machinery is activated during the execution of apoptosis. Once PS is exposed at the cell surface it exhibits procoagulant and proinflammatory activities. Annexin V will bind to the PS-exposing apoptotic cell and can inhibit the procoagulant and proinflammatory activities of the dying cell. These findings together with the presence of Annexin V in the extracellular space depict a novel pathophysiological significance for Annexin V in vivo. The occurrence of autoantibodies to annexin V has been described in several pathological disorders. It is concluded that extracellular annexin V provides an antigenic stimulus for autoantibody production. Such autoantibodies may have a detrimental role interfering with putative functions of annexin V. So it has been shown that concentration of anti-annexin V autoantibodies were significantly raised in sera from patients with rheumatoid arthritis compared to normal controls. Elevation in the anti-Annexin V levels were furthermore detected in patients with Systemic lupus erythematosus (SLE), in these CASE higher incidences of arterial or venous thrombosis, intrauterine fetal loss and prolonged activated partial thromboplastin time were found (5,6). Anti-annexin V antibodies in sera from patients with lupus anticoagulant (LAC) were shown to exhibit anti-phospholipid and LAC properties. The presence of antibodies to Annexin V has furthermore been hypothesized to play a role in recurrent abortions, preeclampsia and fetal death.

References to Summary

References to Anti-Annexin V

  • Benz J, Hofmann A. Annexins: from structure to function. Biol Chem. 1997 Mar-Apr;378 (3-4):177-83
  • Dubois T, Oudinet JP, Mira JP, Russo-Marie F. Annexins and protein kinases C. Biochim Biophys Acta. 1996 Oct 11;1313 (3):290-4
  • Galli M. Non beta 2-glycoprotein I cofactors for antiphospholipid antibodies. Lupus. 1996 Oct;5 (5):388-92
  • Huber R, Berendes R, Burger A, Luecke H, Karshikov A. Annexin V-crystal structure and its implications on function. Behring Inst Mitt. 1992 Apr; (91):107-25
  • Kaburaki J, Ikeda Y. [Thrombosis in patients with SLE and antiphospholipid syndrome]. Rinsho Ketsueki. 1995 Apr;36 (4):320-4
  • Kaburaki J, Kuwana M, Yamamoto M, Kawai S, Ikeda Y. Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus. Am J Hematol. 1997 Mar;54 (3):209-13
  • Kuragaki C, Kidoguchi K, Nakamura N, Wada Y. Anti-annexin V antibodies in plasma and serum samples from patients with lupus anticoagulant. Am J Hematol. 1995 Sep;50 (1):68
  • Matsuda J, Gotoh M, Saitoh N, Gohchi K, Tsukamoto M, Yamamoto T. Anti-annexin antibody in the sera of patients with habitual fetal loss or preeclampsia. Thromb Res. 1994 Jul 1;75 (1):105-6
  • Matsuda J, Saitoh N, Gohchi K, Gotoh M, Tsukamoto M. Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody. Am J Hematol. 1994 Sep;47 (1):56-8
  • Nakamura N, Kuragaki C, Shidara Y, Yamaji K, Wada Y. Antibody to annexin V has anti-phospholipid and lupus anticoagulant properties. Am J Hematol. 1995 Aug;49 (4):347-8
  • Nakamura N, Shidara Y, Kawaguchi N, Azuma C, Mitsuda N, Onishi S, Yamaji K, Wada Y. Lupus anticoagulant autoantibody induces apoptosis in umbilical vein endothelial cells: involvement of annexin V. Biochem Biophys Res Commun. 1994 Dec 15;205 (2):1488-93
  • Reutelingsperger CP, van Heerde WL. Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci. 1997 Jun;53 (6):527-32
  • Rodriguez-Garcia MI, Fernandez JA, Rodriguez A, Fernandez MP, Gutierrez C, Torre-Alonso JC. Annexin V autoantibodies in rheumatoid arthritis. Ann Rheum Dis. 1996 Dec;55 (12):895-900
  • von der Mark K, Mollenhauer J. Annexin V interactions with collagen. Cell Mol Life Sci. 1997 Jun;53 (6):539-45
Related Products Documents